Refine
Has Fulltext
- yes (17)
Is part of the Bibliography
- yes (17)
Year of publication
Document Type
- Journal article (16)
- Doctoral Thesis (1)
Keywords
- multiple sclerosis (5)
- Myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) (3)
- Neuromyelitis optica spectrum disorders (NMOSD) (3)
- Optic neuritis (3)
- Autoantibodies (2)
- Cerebrospinal fluid (2)
- Longitudinally extensive transverse myelitis (LETM) (2)
- MS (2)
- Multiple sclerosis (2)
- Antibody index (1)
- Aquaporin-4 antibodies (AQP4-Ig, NMO-IgG)G (1)
- Aquaporin-4 antibodies (AQP4-IgG) (1)
- Aquaporin-4 antibodies (AQP4-IgG, NMO-IgG) (1)
- Ataxia (1)
- Azathioprine (1)
- Barkhof criteria (1)
- Biomarker (1)
- Brainstem encephalitis (1)
- CBP (1)
- CSF (1)
- CXCL5 (1)
- CXCL8 (1)
- CXCR2 (1)
- Cell-based assays (1)
- Cerebellitis (1)
- Devic syndrome (1)
- Devic’s syndrome (1)
- Diplopia Internuclear ophthalmoplegia (INO) (1)
- Electrophysiology (1)
- Evoked potentials (1)
- Facial nerve palsy (1)
- Gehirn (1)
- Glatiramer acetate (1)
- Hearing loss (1)
- IL-22 binding protein isoform (1)
- IL22RA2 (1)
- IPND criteria (1)
- Infections (1)
- Interferon beta (1)
- International consensus diagnostic criteria for neuromyelitis optica spectrum disorders (1)
- Intractable nausea and vomiting (1)
- Longitudinally extensive transverse myelitis (1)
- Lysosomal storage disease (1)
- MOG-IgG (1)
- MRI criteria (1)
- Magnetic resonance imaging (1)
- McDonald criteria (1)
- Medizin (1)
- Methotrexate (1)
- Myelin oligodendrocyte glycoprotein (MOG) antibodies (1)
- Myelitis (1)
- NF-AT (1)
- NF-\(\kappa\)B (1)
- NFAT (1)
- NMO-IgG (1)
- Natalizumab (1)
- Neurodegeneration (1)
- Neuromyelitis optica (NMO) (1)
- Neuromyelitis optica antibodies (NMO-IgG) (1)
- Neuronal ceroid lipofuscinosis (1)
- OCB (1)
- Ofatumumab (1)
- Oligoclonal bands (1)
- Optical coherence tomography (1)
- Outcome (1)
- Pregnancy (1)
- Rac (1)
- Raf (1)
- Respiratory insufficiency (1)
- Retinal degeneration (1)
- Rhombencephalitis (1)
- Rituximab (1)
- SB332235 (1)
- TAD-A (1)
- Therapy (1)
- Transverse Myelitis (1)
- Transverse myelitis (1)
- Treatment (1)
- Ureaplasma species (1)
- VCAM-1 (1)
- Vaccination (1)
- Wingerchuk criteria 2006 and 2015 (1)
- acid sphingomyelinase (1)
- antidepressants (1)
- aquaporin-4 antibodies (AQP4-IgG) (1)
- association (1)
- atypical chemokine receptor 3 (1)
- autoimmune (1)
- barrier integrity (1)
- biomarker (1)
- blood-brain barrier (1)
- blood–brain barrier (1)
- cell adhesion (1)
- cerebrospinal fluid (1)
- conversion (1)
- criteria (1)
- differential diagnosis (1)
- dimethyl fumarate (1)
- drug (1)
- endothelial cells (1)
- gene (1)
- genetics (1)
- human brain microvascular endothelial cells (1)
- human cerebral endothelial cells (1)
- interleukin-8 (1)
- linkage (1)
- major depression (1)
- meningitis (1)
- monomethyl fumarate (1)
- multiple sklerosis (1)
- mutation (1)
- nervous-system (1)
- neuroinflammation (1)
- neuromyelitis optica (1)
- neuromyelitis optica spectrum disorders (NMOSD) (1)
- optic neuritis (1)
- optical coherence tomography (1)
- p300 (1)
- p38 mitogen-activated protein kinase (1)
- plasminogen (1)
- potent inducer (1)
- proteins (1)
- regulatory T cells (1)
- retinal neuro-axonal damage (1)
- serum (1)
- signal peptide (1)
- sphingolipids (1)
- visual acuity (1)
- visual evoked potentials (1)
Institute
- Neurologische Klinik und Poliklinik (13)
- Pathologisches Institut (3)
- Institut für Virologie und Immunbiologie (2)
- Kinderklinik und Poliklinik (2)
- Augenklinik und Poliklinik (1)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (1)
- Institut für Hygiene und Mikrobiologie (1)
- Institut für Klinische Neurobiologie (1)
- Institut für Organische Chemie (1)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (1)
Background: An inducible release of soluble junctional adhesion molecule-A (sJAM-A) under pro-inflammatory conditions was described in cultured non-CNS endothelial cells (EC) and increased sJAM-A serum levels were found to indicate inflammation in non-CNS vascular beds. Here we studied the regulation of JAM-A expression in cultured brain EC and evaluated sJAM-A as a serum biomarker of blood-brain barrier (BBB) function. Methodology/Principal Findings: As previously reported in non-CNS EC types, pro-inflammatory stimulation of primary or immortalized (hCMEC/D3) human brain microvascular EC (HBMEC) induced a redistribution of cell-bound JAM-A on the cell surface away from tight junctions, along with a dissociation from the cytoskeleton. This was paralleled by reduced immunocytochemical staining of occludin and zonula occludens-1 as well as by increased paracellular permeability for dextran 3000. Both a self-developed ELISA test and Western blot analysis detected a constitutive sJAM-A release by HBMEC into culture supernatants, which importantly was unaffected by pro-inflammatory or hypoxia/reoxygenation challenge. Accordingly, serum levels of sJAM-A were unaltered in 14 patients with clinically active multiple sclerosis compared to 45 stable patients and remained unchanged in 13 patients with acute ischemic non-small vessel stroke over time. Conclusion: Soluble JAM-A was not suited as a biomarker of BBB breakdown in our hands. The unexpected non-inducibility of sJAM-A release at the human BBB might contribute to a particular resistance of brain EC to inflammatory stimuli, protecting the CNS compartment.